The biology and functional importance of MAIT cells

Abstract

In recent years, a population of unconventional T cells called ‘mucosal-associated invariant T cells’ (MAIT cells) has captured the attention of immunologists and clinicians due to their abundance in humans, their involvement in a broad range of infectious and non-infectious diseases and their unusual specificity for microbial riboflavin-derivative antigens presented by the major histocompatibility complex (MHC) class I–like protein MR1. MAIT cells use a limited T cell antigen receptor (TCR) repertoire with public antigen specificities that are conserved across species. They can be activated by TCR-dependent and TCR-independent mechanisms and exhibit rapid, innate-like effector responses. Here we review evidence showing that MAIT cells are a key component of the immune system and discuss their basic biology, development, role in disease and immunotherapeutic potential.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: A timeline highlighting some of the key events in the field of MAIT cell biology.
Fig. 2: MR1-restricted T cell characteristics in humans and mice.
Fig. 3: MAIT cell activation.
Fig. 4: Development of MAIT cells in mice and humans.

References

  1. 1.

    Salio, M., Silk, J. D., Jones, E. Y. & Cerundolo, V. Biology of CD1- and MR1-restricted T cells. Annu. Rev. Immunol. 32, 323–366 (2014).

  2. 2.

    Godfrey, D. I., Uldrich, A. P., McCluskey, J., Rossjohn, J. & Moody, D. B. The burgeoning family of unconventional T cells. Nat. Immunol. 16, 1114–1123 (2015).

  3. 3.

    Porcelli, S., Yockey, C. E., Brenner, M. B. & Balk, S. P. Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD48 α/β T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain. J. Exp. Med. 178, 1–16 (1993). Ref. 3 is the first publication to describe the invariant TRAV1-2 + TRAJ33 + TCR α-chain that defines MAIT cells.

  4. 4.

    Tilloy, F. et al. An invariant T cell receptor alpha chain defines a novel TAP-independent major histocompatibility complex class Ib-restricted alpha/beta T cell subpopulation in mammals. J. Exp. Med. 189, 1907–1921 (1999). Ref. 4 is the first publication to describe the existence of TRAV1 + TRAJ33 + T cells in mice and to investigate TRAV1-2 + TRAJ33 + T cells in humans.

  5. 5.

    Treiner, E. et al. Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. Nature 422, 164–169 (2003). Ref. 5 defined MR1 as the restriction element for MAIT cells and also demonstrated their enrichment in mucosal tissues and coined the term ‘mucosal-associated invariant T cells’.

  6. 6.

    Hashimoto, K., Hirai, M. & Kurosawa, Y. A gene outside the human MHC related to classical HLA class I genes. Science 269, 693–695 (1995).

  7. 7.

    Riegert, P., Wanner, V. & Bahram, S. Genomics, isoforms, expression, and phylogeny of the MHC class I-related MR1 gene. J. Immunol. 161, 4066–4077 (1998).

  8. 8.

    Huang, S. et al. MR1 antigen presentation to mucosal-associated invariant T cells was highly conserved in evolution. Proc. Natl Acad. Sci. USA 106, 8290–8295 (2009).

  9. 9.

    Boudinot, P. et al. Restricting nonclassical MHC genes coevolve with TRAV genes used by innate-like T cells in mammals. Proc. Natl Acad. Sci. USA 113, E2983–E2992 (2016).

  10. 10.

    Le Bourhis, L. et al. Antimicrobial activity of mucosal-associated invariant T cells. Nat. Immunol. 11, 701–708 (2010). Refs. 10 and 13 demonstrated that MAIT cells in mice and humans can respond to diverse microbial species, including bacteria and yeast, in an MR1-dependent manner.

  11. 11.

    Gherardin, N. A. et al. Human blood MAIT cell subsets defined using MR1 tetramers. Immunol. Cell Biol. 96, 507–525 (2018).

  12. 12.

    Dusseaux, M. et al. Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood 117, 1250–1259 (2011).

  13. 13.

    Gold, M. C. et al. Human mucosal associated invariant T cells detect bacterially infected cells. PLoS Biol. 8, e1000407 (2010).

  14. 14.

    Kjer-Nielsen, L. et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 491, 717–723 (2012). Ref. 14 was the first demonstration that derivatives of vitamin B2 and vitamin B9 bind to MR1 and that vitamin B2 derivatives are agonists for MAIT cells.

  15. 15.

    Corbett, A. J. et al. T-cell activation by transitory neo-antigens derived from distinct microbial pathways. Nature 509, 361–365 (2014). Ref. 15 defined the key MR1-bound antigens for MAIT cell activation as 5-OP-RU and 5-OE-RU.

  16. 16.

    Eckle, S. B. et al. A molecular basis underpinning the T cell receptor heterogeneity of mucosal-associated invariant T cells. J. Exp. Med. 211, 1585–1600 (2014).

  17. 17.

    Tastan, C. et al. Tuning of human MAIT cell activation by commensal bacteria species and MR1-dependent T-cell presentation. Mucosal Immunol. 11, 1591–1605 (2018).

  18. 18.

    Kurioka, A. et al. Diverse Streptococcus pneumoniae strains drive a mucosal-associated invariant T-cell response through major histocompatibility complex class I-related molecule-dependent and cytokine-driven pathways. J. Infect. Dis. 217, 988–999 (2018).

  19. 19.

    Soudais, C. et al. In vitro and in vivo analysis of the Gram-negative bacteria-derived riboflavin precursor derivatives activating mouse MAIT cells. J. Immunol. 194, 4641–4649 (2015).

  20. 20.

    Reantragoon, R. et al. Antigen-loaded MR1 tetramers define T cell receptor heterogeneity in mucosal-associated invariant T cells. J. Exp. Med. 210, 2305–2320 (2013). Ref. 20 described the development of MR1-tetramers and defined MAIT cells expressing TRAV1-2 with other TRAJ genes, including TRAJ12 and TRAJ20.

  21. 21.

    Rahimpour, A. et al. Identification of phenotypically and functionally heterogeneous mouse mucosal-associated invariant T cells using MR1 tetramers. J. Exp. Med. 212, 1095–1108 (2015). Ref. 21 was the first paper to characterize MAIT cells through the use of an MR1 tetramer in wild-type mice.

  22. 22.

    Chen, Z. et al. Mucosal-associated invariant T-cell activation and accumulation after in vivo infection depends on microbial riboflavin synthesis and co-stimulatory signals. Mucosal Immunol. 10, 58–68 (2017).

  23. 23.

    Patel, O. et al. Recognition of vitamin B metabolites by mucosal-associated invariant T cells. Nat. Commun. 4, 2142 (2013).

  24. 24.

    López-Sagaseta, J. et al. The molecular basis for mucosal-associated invariant T cell recognition of MR1 proteins. Proc. Natl Acad. Sci. USA 110, E1771–E1778 (2013). Refs. 23 and 24 show the ternary complex of a MAIT cell TCR bound to MR1 plus antigen.

  25. 25.

    Reantragoon, R. et al. Structural insight into MR1-mediated recognition of the mucosal associated invariant T cell receptor. J. Exp. Med. 209, 761–774 (2012).

  26. 26.

    Gherardin, N. A. et al. Diversity of T cells restricted by the MHC class I-related molecule MR1 facilitates differential antigen recognition. Immunity 44, 32–45 (2016). Refs. 26 and 35 were the first demonstrations that other TCR α-chains can confer MR1 reactivity that leads to differential antigen recognition relative to that of MAIT cells.

  27. 27.

    McWilliam, H. E. et al. The intracellular pathway for the presentation of vitamin B-related antigens by the antigen-presenting molecule MR1. Nat. Immunol. 17, 531–537 (2016).

  28. 28.

    Kjer-Nielsen, L. et al. An overview on the identification of MAIT cell antigens. Immunol. Cell Biol. 96, 573–587 (2018).

  29. 29.

    McWilliam, H. E. & Villadangos, J. A. MR1 antigen presentation to MAIT cells: new ligands, diverse pathways? Curr. Opin. Immunol. 52, 108–113 (2018).

  30. 30.

    Keller, A. N. et al. Drugs and drug-like molecules can modulate the function of mucosal-associated invariant T cells. Nat. Immunol. 18, 402–411 (2017).

  31. 31.

    Harriff, M. J. et al. MR1 displays the microbial metabolome driving selective MR1-restricted T cell receptor usage. Sci. Immunol. 3, eaao2556 (2018).

  32. 32.

    Koay, H. F. et al. A three-stage intrathymic development pathway for the mucosal-associated invariant T cell lineage. Nat. Immunol. 17, 1300–1311 (2016). Ref. 32 was the demonstration that mouse and human MAIT cells follow a three-stage intrathymic developmental pathway.

  33. 33.

    Gherardin, N. A. et al. Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma. Sci. Rep. 8, 4159 (2018).

  34. 34.

    Lepore, M. et al. Functionally diverse human T cells recognize non-microbial antigens presented by MR1. eLife 6, e24476 (2017).

  35. 35.

    Meermeier, E. W. et al. Human TRAV1-2-negative MR1-restricted T cells detect S. pyogenes and alternatives to MAIT riboflavin-based antigens. Nat. Commun. 7, 12506 (2016).

  36. 36.

    Dias, J. et al. The CD4CD8 MAIT cell subpopulation is a functionally distinct subset developmentally related to the main CD8+ MAIT cell pool. Proc. Natl Acad. Sci. USA 115, E11513–E11522 (2018).

  37. 37.

    Leeansyah, E. et al. Activation, exhaustion, and persistent decline of the antimicrobial MR1-restricted MAIT-cell population in chronic HIV-1 infection. Blood 121, 1124–1135 (2013).

  38. 38.

    Koppejan, H. et al. Altered composition and phenotype of mucosal-associated invariant T cells in early untreated rheumatoid arthritis. Arthritis Res. Ther. 21, 3 (2019).

  39. 39.

    Sobkowiak, M. J. et al. Tissue-resident MAIT cell populations in human oral mucosa exhibit an activated profile and produce IL-17. Eur. J. Immunol. 49, 133–143 (2019).

  40. 40.

    Cui, Y. et al. Mucosal-associated invariant T cell-rich congenic mouse strain allows functional evaluation. J. Clin. Invest. 125, 4171–4185 (2015).

  41. 41.

    Croxford, J. L., Miyake, S., Huang, Y. Y., Shimamura, M. & Yamamura, T. Invariant Vα19i T cells regulate autoimmune inflammation. Nat. Immunol. 7, 987–994 (2006).

  42. 42.

    Kawachi, I., Maldonado, J., Strader, C. & Gilfillan, S. MR1-restricted Vα19i mucosal-associated invariant T cells are innate T cells in the gut lamina propria that provide a rapid and diverse cytokine response. J. Immunol. 176, 1618–1627 (2006).

  43. 43.

    Martin, E. et al. Stepwise development of MAIT cells in mouse and human. PLoS Biol. 7, e54 (2009).

  44. 44.

    Sakala, I. G. et al. Functional heterogeneity and antimycobacterial effects of mouse mucosal-associated invariant T cells specific for riboflavin metabolites. J. Immunol. 195, 587–601 (2015).

  45. 45.

    Koay, H. F. et al. Diverse MR1-restricted T cells in mice and humans. Nat. Commun. 10, 2243 (2019).

  46. 46.

    Seach, N. et al. Double-positive thymocytes select mucosal-associated invariant T cells. J. Immunol. 191, 6002–6009 (2013).

  47. 47.

    Koay, H. F., Godfrey, D. I. & Pellicci, D. G. Development of mucosal-associated invariant T cells. Immunol. Cell Biol. 96, 598–606 (2018).

  48. 48.

    Salou, M. et al. A common transcriptomic program acquired in the thymus defines tissue residency of MAIT and NKT subsets. J. Exp. Med. 216, 133–151 (2019).

  49. 49.

    Gutierrez-Arcelus, M. et al. Lymphocyte innateness defined by transcriptional states reflects a balance between proliferation and effector functions. Nat. Commun. 10, 687 (2019).

  50. 50.

    Winter, S. J. et al. MicroRNA miR-181a/b-1 controls MAIT cell development. Immunol. Cell Biol. 97, 190–202 (2019).

  51. 51.

    Beaulieu, A. M. & Sant’Angelo, D. B. The BTB-ZF family of transcription factors: key regulators of lineage commitment and effector function development in the immune system. J. Immunol. 187, 2841–2847 (2011).

  52. 52.

    Novak, J., Dobrovolny, J., Novakova, L. & Kozak, T. The decrease in number and change in phenotype of mucosal-associated invariant T cells in the elderly and differences in men and women of reproductive age. Scand. J. Immunol. 80, 271–275 (2014).

  53. 53.

    Walker, L. J., Tharmalingam, H. & Klenerman, P. The rise and fall of MAIT cells with age. Scand. J. Immunol. 80, 462–463 (2014).

  54. 54.

    Leeansyah, E., Loh, L., Nixon, D. F. & Sandberg, J. K. Acquisition of innate-like microbial reactivity in mucosal tissues during human fetal MAIT-cell development. Nat. Commun. 5, 3143 (2014).

  55. 55.

    Le Bourhis, L. et al. MAIT cells detect and efficiently lyse bacterially-infected epithelial cells. PLoS Pathog. 9, e1003681 (2013).

  56. 56.

    Kurioka, A. et al. MAIT cells are licensed through granzyme exchange to kill bacterially sensitized targets. Mucosal Immunol. 8, 429–440 (2015).

  57. 57.

    Wang, H. et al. MAIT cells protect against pulmonary Legionella longbeachae infection. Nat. Commun. 9, 3350 (2018).

  58. 58.

    Kurioka, A. et al. Shared and distinct phenotypes and functions of human CD161++ Vα7.2+ T cell subsets. Front. Immunol. 8, 1031 (2017).

  59. 59.

    Tang, X. Z. et al. IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells. J. Immunol. 190, 3142–3152 (2013).

  60. 60.

    Gibbs, A. et al. MAIT cells reside in the female genital mucosa and are biased towards IL-17 and IL-22 production in response to bacterial stimulation. Mucosal Immunol. 10, 35–45 (2017).

  61. 61.

    Lepore, M. et al. Parallel T-cell cloning and deep sequencing of human MAIT cells reveal stable oligoclonal TCRβ repertoire. Nat. Commun. 5, 3866 (2014).

  62. 62.

    Slichter, C. K. et al. Distinct activation thresholds of human conventional and innate-like memory T cells. JCI Insight 1, e86292 (2016).

  63. 63.

    Turtle, C. J. et al. Innate signals overcome acquired TCR signaling pathway regulation and govern the fate of human CD161hi CD8α+ semi-invariant T cells. Blood 118, 2752–2762 (2011).

  64. 64.

    Havenith, S. H. et al. Analysis of stem-cell-like properties of human CD161++IL-18Rα+ memory CD8+ T cells. Int. Immunol. 24, 625–636 (2012).

  65. 65.

    Ussher, J. E. et al. CD161++ CD8+ T cells, including the MAIT cell subset, are specifically activated by IL-12 + IL-18 in a TCR-independent manner. Eur. J. Immunol. 44, 195–203 (2014).

  66. 66.

    van Wilgenburg, B. et al. MAIT cells are activated during human viral infections. Nat. Commun. 7, 11653 (2016). Ref. 66 was the first demonstration that MAIT cells can respond to a range of viruses.

  67. 67.

    Sattler, A., Dang-Heine, C., Reinke, P. & Babel, N. IL-15 dependent induction of IL-18 secretion as a feedback mechanism controlling human MAIT-cell effector functions. Eur. J. Immunol. 45, 2286–2298 (2015).

  68. 68.

    Leeansyah, E. et al. Arming of MAIT cell cytolytic antimicrobial activity is induced by IL-7 and defective in HIV-1 Infection. PLoS Pathog. 11, e1005072 (2015).

  69. 69.

    Gracey, E. et al. IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis. Ann. Rheum. Dis. 75, 2124–2132 (2016).

  70. 70.

    Salio, M. et al. Activation of human mucosal-associated invariant T cells induces CD40L-dependent maturation of monocyte-derived and primary dendritic cells. J. Immunol. 199, 2631–2638 (2017).

  71. 71.

    Gold, M. C. et al. Human thymic MR1-restricted MAIT cells are innate pathogen-reactive effectors that adapt following thymic egress. Mucosal Immunol. 6, 35–44 (2013).

  72. 72.

    Brozova, J., Karlova, I. & Novak, J. Analysis of the phenotype and function of the subpopulations of mucosal-associated invariant T cells. Scand. J. Immunol. 84, 245–251 (2016).

  73. 73.

    Davanian, H. et al. Mucosal-associated invariant T cells and oral microbiome in persistent apical periodontitis. Int. J. Oral Sci. 11, 16 (2019).

  74. 74.

    Dias, J., Leeansyah, E. & Sandberg, J. K. Multiple layers of heterogeneity and subset diversity in human MAIT cell responses to distinct microorganisms and to innate cytokines. Proc. Natl Acad. Sci. USA 114, E5434–E5443 (2017).

  75. 75.

    Voillet, V. et al. Human MAIT cells exit peripheral tissues and recirculate via lymph in steady state conditions. JCI Insight 3, e98487 (2018).

  76. 76.

    Lee, C.H. et al. C/EBPδ drives interactions between human MAIT cells and endothelial cells that are important for extravasation. eLife 7, (2018).

  77. 77.

    Gherardin, N. A., McCluskey, J., Rossjohn, J. & Godfrey, D. I. The diverse family of MR1-restricted T cells. J. Immunol. 201, 2862–2871 (2018).

  78. 78.

    Harriff, M. J. et al. Endosomal MR1 trafficking plays a key role in presentation of Mycobacterium tuberculosis ligands to MAIT cells. PLoS Pathog. 12, e1005524 (2016).

  79. 79.

    Ben Youssef, G. et al. Ontogeny of human mucosal-associated invariant T cells and related T cell subsets. J. Exp. Med. 215, 459–479 (2018).

  80. 80.

    Georgel, P., Radosavljevic, M., Macquin, C. & Bahram, S. The non-conventional MHC class I MR1 molecule controls infection by Klebsiella pneumoniae in mice. Mol. Immunol. 48, 769–775 (2011).

  81. 81.

    Chua, W. J. et al. Polyclonal mucosa-associated invariant T cells have unique innate functions in bacterial infection. Infect. Immun. 80, 3256–3267 (2012).

  82. 82.

    Meierovics, A., Yankelevich, W. J. & Cowley, S. C. MAIT cells are critical for optimal mucosal immune responses during in vivo pulmonary bacterial infection. Proc. Natl Acad. Sci. USA 110, E3119–E3128 (2013).

  83. 83.

    Meierovics, A. I. & Cowley, S. C. MAIT cells promote inflammatory monocyte differentiation into dendritic cells during pulmonary intracellular infection. J. Exp. Med. 213, 2793–2809 (2016).

  84. 84.

    Grimaldi, D. et al. Specific MAIT cell behaviour among innate-like T lymphocytes in critically ill patients with severe infections. Intensive Care Med. 40, 192–201 (2014).

  85. 85.

    Pincikova, T. et al. Severely impaired control of bacterial infections in a patient with cystic fibrosis defective in mucosal-associated invariant T cells. Chest 153, e93–e96 (2018).

  86. 86.

    Smith, D. J., Hill, G. R., Bell, S. C. & Reid, D. W. Reduced mucosal associated invariant T-cells are associated with increased disease severity and Pseudomonas aeruginosa infection in cystic fibrosis. PLoS One 9, e109891 (2014).

  87. 87.

    D’Souza, C. et al. Mucosal-associated invariant T cells augment immunopathology and gastritis in chronic Helicobacter pylori infection. J. Immunol. 200, 1901–1916 (2018).

  88. 88.

    Booth, J. S. et al. Mucosal-associated invariant T cells in the human gastric mucosa and blood: role in Helicobacter pylori infection. Front. Immunol. 6, 466 (2015).

  89. 89.

    Salerno-Goncalves, R. et al. Challenge of humans with wild-type Salmonella enterica serovar Typhi elicits changes in the activation and homing characteristics of mucosal-associated invariant T cells. Front. Immunol. 8, 398 (2017).

  90. 90.

    Howson, L. J. et al. MAIT cell clonal expansion and TCR repertoire shaping in human volunteers challenged with Salmonella Paratyphi A. Nat. Commun. 9, 253 (2018).

  91. 91.

    Loh, L. et al. Human mucosal-associated invariant T cells contribute to antiviral influenza immunity via IL-18-dependent activation. Proc. Natl Acad. Sci. USA 113, 10133–10138 (2016).

  92. 92.

    Wilgenburg, B. V. et al. MAIT cells contribute to protection against lethal influenza infection in vivo. Nat. Commun. 9, 4706 (2018).

  93. 93.

    Boeijen, L. L. et al. Mucosal-associated invariant T cells are more activated in chronic hepatitis B, but not depleted in blood: reversal by antiviral therapy. J. Infect. Dis. 216, 969–976 (2017).

  94. 94.

    Yong, Y. K. et al. Hyper-expression of PD-1 is associated with the levels of exhausted and dysfunctional phenotypes of circulating CD161++TCR iVα7.2+ mucosal-associated invariant T cells in chronic hepatitis B virus infection. Front. Immunol. 9, 472 (2018).

  95. 95.

    Yong, Y. K. et al. Decrease of CD69 levels on TCR Vα7.2+CD4+ innate-like lymphocytes is associated with impaired cytotoxic functions in chronic hepatitis B virus-infected patients. Innate Immun. 23, 459–467 (2017).

  96. 96.

    Barathan, M. et al. Peripheral loss of CD8+ CD161++ TCRVα7·2+ mucosal-associated invariant T cells in chronic hepatitis C virus-infected patients. Eur. J. Clin. Invest. 46, 170–180 (2016).

  97. 97.

    Beudeker, B. J. B. et al. Mucosal-associated invariant T-cell frequency and function in blood and liver of HCV mono- and HCV/HIV co-infected patients with advanced fibrosis. Liver Int. 38, 458–468 (2018).

  98. 98.

    Bolte, F. J. et al. Intra-hepatic depletion of mucosal-associated invariant T cells in hepatitis C virus-induced liver inflammation. Gastroenterology 153, 1392–1403.e1392 (2017).

  99. 99.

    Eberhard, J. M. et al. Reduced CD161+ MAIT cell frequencies in HCV and HIV/HCV co-infection: is the liver the heart of the matter? J. Hepatol. 65, 1261–1263 (2016).

  100. 100.

    Hengst, J. et al. Nonreversible MAIT cell-dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapy. Eur. J. Immunol. 46, 2204–2210 (2016).

  101. 101.

    Muttiah, B. et al. Peripheral loss of CD8 CD161 TCRVα7.2 MAIT cells in chronic HCV-infected patients. Eur. J. Clin. Invest. 46, 170–180 (2015).

  102. 102.

    Spaan, M. et al. Frequencies of circulating MAIT cells are diminished in chronic HCV, HIV and HCV/HIV co-infection and do not recover during therapy. PLoS One 11, e0159243 (2016).

  103. 103.

    Juno, J. A., Phetsouphanh, C., Klenerman, P. & Kent, S. J. Perturbation of mucosal-associated invariant T cells and iNKT cells in HIV infection. Curr. Opin. HIV AIDS 14, 77–84 (2019).

  104. 104.

    Ussher, J. E., Willberg, C. B. & Klenerman, P. MAIT cells and viruses. Immunol. Cell Biol. 96, 630–641 (2018).

  105. 105.

    Illés, Z., Shimamura, M., Newcombe, J., Oka, N. & Yamamura, T. Accumulation of Vα7.2-Jα33 invariant T cells in human autoimmune inflammatory lesions in the nervous system. Int. Immunol. 16, 223–230 (2004).

  106. 106.

    Abrahamsson, S. V. et al. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. Brain 136, 2888–2903 (2013).

  107. 107.

    Willing, A. et al. CD8+ MAIT cells infiltrate into the CNS and alterations in their blood frequencies correlate with IL-18 serum levels in multiple sclerosis. Eur. J. Immunol. 44, 3119–3128 (2014).

  108. 108.

    Held, K. et al. αβ T-cell receptors from multiple sclerosis brain lesions show MAIT cell–related features. Neurol. Neuroimmunol. Neuroinflamm. 2, e107 (2015).

  109. 109.

    Salou, M. et al. Neuropathologic, phenotypic and functional analyses of mucosal associated invariant T cells in multiple sclerosis. Clin. Immunol. 166-167, 1–11 (2016).

  110. 110.

    Miyazaki, Y., Miyake, S., Chiba, A., Lantz, O. & Yamamura, T. Mucosal-associated invariant T cells regulate Th1 response in multiple sclerosis. Int. Immunol. 23, 529–535 (2011).

  111. 111.

    Annibali, V. et al. CD161highCD8+ T cells bear pathogenetic potential in multiple sclerosis. Brain 134, 542–554 (2011).

  112. 112.

    Sugimoto, C. et al. The dynamics of mucosal-associated invariant T cells in multiple sclerosis. Springerplus 5, 1259 (2016).

  113. 113.

    Buscarinu, M. C. et al. Intestinal permeability in relapsing-remitting multiple sclerosis. Neurotherapeutics 15, 68–74 (2018).

  114. 114.

    Willing, A., Jäger, J., Reinhardt, S., Kursawe, N. & Friese, M. A. Production of IL-17 by MAIT cells is increased in multiple sclerosis and is associated with IL-7 receptor expression. J. Immunol. 200, 974–982 (2018).

  115. 115.

    Hiejima, E. et al. Reduced numbers and proapoptotic features of mucosal-associated invariant T Cells as a characteristic finding in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 21, 1529–1540 (2015).

  116. 116.

    Haga, K. et al. MAIT cells are activated and accumulated in the inflamed mucosa of ulcerative colitis. J. Gastroenterol. Hepatol. 31, 965–972 (2016).

  117. 117.

    Serriari, N. E. et al. Innate mucosal-associated invariant T (MAIT) cells are activated in inflammatory bowel diseases. Clin. Exp. Immunol. 176, 266–274 (2014).

  118. 118.

    Tominaga, K. et al. Possible involvement of mucosal-associated invariant T cells in the progression of inflammatory bowel diseases. Biomed. Res. 38, 111–121 (2017).

  119. 119.

    Dunne, M. R. et al. Persistent changes in circulating and intestinal γδ T cell subsets, invariant natural killer T cells and mucosal-associated invariant T cells in children and adults with coeliac disease. PLoS One 8, e76008 (2013).

  120. 120.

    Eyerich, K., Dimartino, V. & Cavani, A. IL-17 and IL-22 in immunity: driving protection and pathology. Eur. J. Immunol. 47, 607–614 (2017).

  121. 121.

    Cho, Y. N. et al. Mucosal-associated invariant T cell deficiency in systemic lupus erythematosus. J. Immunol. 193, 3891–3901 (2014).

  122. 122.

    Hayashi, E. et al. Involvement of mucosal-associated invariant T cells in ankylosing spondylitis. J. Rheumatol. 43, 1695–1703 (2016).

  123. 123.

    Kim, M. et al. TNFα and IL-1β in the synovial fluid facilitate mucosal-associated invariant T (MAIT) cell migration. Cytokine 99, 91–98 (2017).

  124. 124.

    Toussirot, É., Laheurte, C., Gaugler, B., Gabriel, D. & Saas, P. Increased IL-22- and IL-17A-producing mucosal-associated invariant T cells in the peripheral blood of patients with ankylosing spondylitis. Front. Immunol. 9, 1610 (2018).

  125. 125.

    Robert, M. & Miossec, P. IL-17 in rheumatoid arthritis and precision medicine: from synovitis expression to circulating bioactive levels. Front. Med. (Lausanne) 5, 364 (2019).

  126. 126.

    Chiba, A. et al. Mucosal-associated invariant T cells promote inflammation and exacerbate disease in murine models of arthritis. Arthritis Rheum. 64, 153–161 (2012).

  127. 127.

    Sugimoto, C. et al. Mucosal-associated invariant T cell is a potential marker to distinguish fibromyalgia syndrome from arthritis. PLoS One 10, e0121124 (2015).

  128. 128.

    Rouxel, O. et al. Cytotoxic and regulatory roles of mucosal-associated invariant T cells in type 1 diabetes. Nature immunology 18, 1321–1331 (2017).

  129. 129.

    Harms, R. Z. et al. Abnormal T cell frequencies, including cytomegalovirus-associated expansions, distinguish seroconverted subjects at risk for type 1 diabetes. Front. Immunol. 9, 2332 (2018).

  130. 130.

    Harms, R. Z., Lorenzo, K. M., Corley, K. P., Cabrera, M. S. & Sarvetnick, N. E. Altered CD161bright CD8+ mucosal associated invariant T (MAIT)-like cell dynamics and increased differentiation states among juvenile type 1 diabetics. PLoS One 10, e0117335 (2015).

  131. 131.

    Kuric, E. et al. No evidence for presence of mucosal-associated invariant T cells in the insulitic lesions in patients recently diagnosed with type 1 diabetes. Am. J. Pathol. 188, 1744–1748 (2018).

  132. 132.

    Shimamura, M. et al. Regulation of immunological disorders by invariant Vα19-Jα33 TCR-bearing cells. Immunobiology 216, 374–378 (2011).

  133. 133.

    Magalhaes, I. et al. Mucosal-associated invariant T cell alterations in obese and type 2 diabetic patients. J. Clin. Invest. 125, 1752–1762 (2015).

  134. 134.

    Carolan, E. et al. Altered distribution and increased IL-17 production by mucosal-associated invariant T cells in adult and childhood obesity. J. Immunol. 194, 5775–5780 (2015).

  135. 135.

    Touch, S. et al. Mucosal-associated invariant T (MAIT) cells are depleted and prone to apoptosis in cardiometabolic disorders. FASEB J, fj201800052RR (2018).

  136. 136.

    Hinks, T. S. et al. Innate and adaptive T cells in asthmatic patients: relationship to severity and disease mechanisms. J. Allergy Clin. Immunol. 136, 323–333 (2015).

  137. 137.

    Chandra, S. et al. Development of asthma in inner-city children: possible roles of MAIT cells and variation in the home environment. J. Immunol. 200, 1995–2003 (2018).

  138. 138.

    Lezmi, G. et al. Circulating IL-17-producing mucosal-associated invariant T cells (MAIT) are associated with symptoms in children with asthma. Clin. Immunol. 188, 7–11 (2018).

  139. 139.

    Lezmi, G. & Leite-de-Moraes, M. C. Comment on “Development of asthma in inner-city children: possible roles of MAIT cells and variation in the home environment”. J. Immunol. 200, 3317 (2018).

  140. 140.

    Chandra, S., Wingender, G., Greenbaum, J. A. & Kronenberg, M. Response to comment on “Development of asthma in inner-city children: possible roles of MAIT cells and variation in the home environment”. J. Immunol. 200, 3317–3318 (2018).

  141. 141.

    Kwon, Y. S. et al. Mucosal-associated invariant T cell deficiency in chronic obstructive pulmonary disease. COPD 13, 196–202 (2016).

  142. 142.

    Hinks, T. S. et al. Steroid-induced deficiency of mucosal-associated invariant T cells in the chronic obstructive pulmonary disease lung. Implications for nontypeable Haemophilus influenzae infection. Am. J. Respir. Crit. Care Med. 194, 1208–1218 (2016).

  143. 143.

    Gentles, A. J. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21, 938–945 (2015).

  144. 144.

    Nitta, T., Oksenberg, J. R., Rao, N. A. & Steinman, L. Predominant expression of T cell receptor Vα7 in tumor-infiltrating lymphocytes of uveal melanoma. Science 249, 672–674 (1990).

  145. 145.

    Ebato, M., Nitta, T., Yagita, H., Sato, K. & Okumura, K. Skewed distribution of TCR Vα7-bearing T cells within tumor-infiltrating lymphocytes of HLA-A24(9)-positive patients with malignant glioma. Immunol. Lett. 39, 53–64 (1993).

  146. 146.

    Ebato, M., Nitta, T., Yagita, H., Sato, K. & Okumura, K. Shared amino acid sequences in the NDβN and Nα regions of the T cell receptors of tumor-infiltrating lymphocytes within malignant glioma. Eur. J. Immunol. 24, 2987–2992 (1994).

  147. 147.

    Peterfalvi, A. et al. Invariant Vα7.2-Jα33 TCR is expressed in human kidney and brain tumors indicating infiltration by mucosal-associated invariant T (MAIT) cells. Int. Immunol. 20, 1517–1525 (2008).

  148. 148.

    Turtle, C. J., Swanson, H. M., Fujii, N., Estey, E. H. & Riddell, S. R. A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy. Immunity 31, 834–844 (2009).

  149. 149.

    Hildebrandt, M. et al. Apheresis-related enrichment of CD26++ T lymphocytes: phenotypic characterization and correlation with unfavorable outcome in autologous hematopoietic progenitor cell transplantation. Transfusion 52, 765–776 (2012).

  150. 150.

    Sundström, P. et al. Human mucosa-associated invariant T cells accumulate in colon adenocarcinomas but produce reduced amounts of IFN-γ. J. Immunol. 195, 3472–3481 (2015).

  151. 151.

    Zabijak, L. et al. Increased tumor infiltration by mucosal-associated invariant T cells correlates with poor survival in colorectal cancer patients. Cancer Immunol. Immunother. 64, 1601–1608 (2015).

  152. 152.

    Ling, L. et al. Circulating and tumor-infiltrating mucosal associated invariant T (MAIT) cells in colorectal cancer patients. Sci. Rep. 6, 20358 (2016).

  153. 153.

    Won, E. J. et al. Clinical relevance of circulating mucosal-associated invariant T cell levels and their anti-cancer activity in patients with mucosal-associated cancer. Oncotarget 7, 76274–76290 (2016).

  154. 154.

    Huang, W. C., Hsiao, Y. C., Wu, C. C., Hsu, Y. T. & Chang, C. L. Less circulating mucosal-associated invariant T cells in patients with cervical cancer. Taiwan. J. Obstet. Gynecol. 58, 117–121 (2019).

  155. 155.

    Shaler, C. R. et al. Mucosa-associated invariant T cells infiltrate hepatic metastases in patients with colorectal carcinoma but are rendered dysfunctional within and adjacent to tumor microenvironment. Cancer Immunol. Immunother. 66, 1563–1575 (2017).

  156. 156.

    Zumwalde, N. A., Haag, J. D., Gould, M. N. & Gumperz, J. E. Mucosal associated invariant T cells from human breast ducts mediate a Th17-skewed response to bacterially exposed breast carcinoma cells. Breast Cancer Res. 20, 111 (2018).

  157. 157.

    Favreau, M. et al. Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibition. Haematologica 102, e266–e270 (2017).

  158. 158.

    Mitchell, J. et al. Altered populations of unconventional T cell lineages in patients with Langerhans cell histiocytosis. Sci. Rep. 8, 16506 (2018).

  159. 159.

    Varelias, A. et al. Recipient mucosal-associated invariant T cells control GVHD within the colon. J. Clin. Invest. 128, 1919–1936 (2018).

  160. 160.

    Kawaguchi, K. et al. Influence of post-transplant mucosal-associated invariant T cell recovery on the development of acute graft-versus-host disease in allogeneic bone marrow transplantation. Int. J. Hematol. 108, 66–75 (2018).

  161. 161.

    Bhattacharyya, A. et al. Graft-derived reconstitution of mucosal-associated invariant T cells after allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 24, 242–251 (2018).

  162. 162.

    Solders, M. et al. Mucosal-associated invariant T cells display a poor reconstitution and altered phenotype after allogeneic hematopoietic stem cell transplantation. Front. Immunol. 8, 1861 (2017).

  163. 163.

    Duan, M. et al. Activated and exhausted MAIT cells foster disease progression and indicate poor outcome in hepatocellular carcinoma. Clin. Cancer Res. 25, 3304–3316 (2019).

  164. 164.

    Zheng, C. et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell 169, 1342–1356.e1316 (2017).

  165. 165.

    McGregor, S. et al. PLZF staining identifies peripheral T-cell lymphomas derived from innate-like T-cells with TRAV1-2-TRAJ33 TCR-α rearrangement. Blood 123, 2742–2743 (2014).

  166. 166.

    Cerundolo, V., Silk, J. D., Masri, S. H. & Salio, M. Harnessing invariant NKT cells in vaccination strategies. Nat. Rev. Immunol. 9, 28–38 (2009).

  167. 167.

    Godfrey, D. I., Le Nours, J., Andrews, D. M., Uldrich, A. P. & Rossjohn, J. Unconventional T cell targets for cancer immunotherapy. Immunity 48, 453–473 (2018).

  168. 168.

    Salerno-Goncalves, R., Rezwan, T. & Sztein, M. B. B cells modulate mucosal associated invariant T cell immune responses. Front. Immunol. 4, 511 (2014).

  169. 169.

    Bernal, I. et al. Clostridioides difficile activates human mucosal-associated invariant T cells. Front. Microbiol. 9, 2532 (2018).

  170. 170.

    Jesteadt, E. et al. Interleukin-18 is critical for mucosa-associated invariant T cell γ interferon responses to Francisella species in vitro but not in vivo. Infect. Immun. 86, e00117–18 (2018).

  171. 171.

    Wallington, J. C., Williams, A. P., Staples, K. J. & Wilkinson, T. M. A. IL-12 and IL-7 synergize to control mucosal-associated invariant T-cell cytotoxic responses to bacterial infection. J. Allergy Clin. Immunol. 141, 2182–2195.e2186 (2018).

  172. 172.

    Maekawa, T. et al. Low mucosal-associated invariant T-cell number in peripheral blood of patients with immune thrombocytopenia and their response to prednisolone. PLoS One 13, e0207149 (2018).

  173. 173.

    Seshadri, C. et al. A polymorphism in human MR1 is associated with mRNA expression and susceptibility to tuberculosis. Genes Immun. 18, 8–14 (2017).

  174. 174.

    Kwon, Y. S. et al. Mucosal-associated invariant T cells are numerically and functionally deficient in patients with mycobacterial infection and reflect disease activity. Tuberculosis (Edinb.). 95, 267–274 (2015).

  175. 175.

    Yang, Q. et al. Discriminating active tuberculosis from latent tuberculosis infection by flow cytometric measurement of CD161-expressing T cells. Sci. Rep. 5, 17918 (2015).

  176. 176.

    Sharma, P. K. et al. High expression of CD26 accurately identifies human bacteria-reactive MR1-restricted MAIT cells. Immunology 145, 443–453 (2015).

  177. 177.

    Wong, E. B. et al. Low levels of peripheral CD161++CD8+ mucosal associated invariant T (MAIT) cells are found in HIV and HIV/TB co-infection. PLoS One 8, e83474 (2013).

  178. 178.

    Saeidi, A. et al. Attrition of TCR Vα7.2+ CD161++ MAIT cells in HIV-tuberculosis co-infection is associated with elevated levels of PD-1 expression. PLoS One 10, e0124659 (2015).

  179. 179.

    Jiang, J. et al. Enhanced immune response of MAIT cells in tuberculous pleural effusions depends on cytokine signaling. Sci. Rep. 6, 32320 (2016).

  180. 180.

    Jiang, J. et al. Mucosal-associated invariant T cells from patients with tuberculosis exhibit impaired immune response. J. Infect. 72, 338–352 (2016).

  181. 181.

    Malka-Ruimy, C. et al. Mucosal-associated invariant T cell levels are reduced in the peripheral blood and lungs of children with active pulmonary tuberculosis. Front. Immunol. 10, 206 (2019).

  182. 182.

    Vorkas, C. K. et al. Mucosal-associated invariant and γδ T cell subsets respond to initial Mycobacterium tuberculosis infection. JCI Insight 3, e121899 (2018).

  183. 183.

    Mendy, J. et al. Changes in Mycobacterium tuberculosis-specific immunity with influenza co-infection at time of TB diagnosis. Front. Immunol. 9, 3093 (2019).

  184. 184.

    Greene, J. M. et al. MR1-restricted mucosal-associated invariant T (MAIT) cells respond to mycobacterial vaccination and infection in nonhuman primates. Mucosal Immunol. 10, 802–813 (2017).

  185. 185.

    Kauffman, K. D. et al. Limited pulmonary mucosal-associated invariant T cell accumulation and activation during Mycobacterium tuberculosis infection in rhesus macaques. Infect. Immun. 86, e00431–18 (2018).

  186. 186.

    Kang, S. J. et al. Activation, impaired tumor necrosis factor-α production, and deficiency of circulating mucosal-associated invariant t cells in patients with scrub typhus. PLoS Negl. Trop. Dis. 10, e0004832 (2016).

  187. 187.

    Leung, D. T. et al. Circulating mucosal associated invariant T cells are activated in Vibrio cholerae O1 infection and associated with lipopolysaccharide antibody responses. PLoS Negl. Trop. Dis. 8, e3076 (2014).

  188. 188.

    Liuzzi, A. R. et al. Unconventional human T cells accumulate at the site of infection in response to microbial ligands and induce local tissue remodeling. J. Immunol. 197, 2195–2207 (2016).

  189. 189.

    Jahreis, S. et al. Human MAIT cells are rapidly activated by Aspergillus spp. in an APC-dependent manner. Eur. J. Immunol. 48, 1698–1706 (2018).

  190. 190.

    Mpina, M. et al. Controlled human malaria infection leads to long-lasting changes in innate and innate-like lymphocyte populations. J. Immunol. 199, 107–118 (2017).

  191. 191.

    Shaler, C. R. et al. MAIT cells launch a rapid, robust and distinct hyperinflammatory response to bacterial superantigens and quickly acquire an anergic phenotype that impedes their cognate antimicrobial function:defining a novel mechanism of superantigen-induced immunopathology and immunosuppression. PLoS Biol. 15, e2001930 (2017).

  192. 192.

    Dias, J. et al. Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells. J. Hepatol. 71, 301–312 (2019).

  193. 193.

    Cannizzo, E.S. et al. Successful direct-acting antiviral therapy in HIV/HCV co-infected patients fails to restore circulating mucosal-associated invariant T cells. Eur. J. Immunol. https://doi.org/10.1002/eji.201948152 (2019).

  194. 194.

    Cosgrove, C. et al. Early and nonreversible decrease of CD161++ /MAIT cells in HIV infection. Blood 121, 951–961 (2013).

  195. 195.

    Greathead, L. et al. CD8+/CD161++ mucosal-associated invariant T-cell levels in the colon are restored on long-term antiretroviral therapy and correlate with CD8+ T-cell immune activation. AIDS 28, 1690–1692 (2014).

  196. 196.

    Eberhard, J. M. et al. CD161+ MAIT cells are severely reduced in peripheral blood and lymph nodes of HIV-infected individuals independently of disease progression. PLoS One 9, e111323 (2014).

  197. 197.

    Fernandez, C. S. et al. MAIT cells are depleted early but retain functional cytokine expression in HIV infection. Immunol. Cell Biol. 93, 177–188 (2015).

  198. 198.

    Ussher, J. E. et al. Molecular analyses define Vα7.2-Jα33+ MAIT cell depletion in HIV infection: a case-control study. Medicine (Baltimore) 94, e1134 (2015).

  199. 199.

    Khaitan, A. et al. HIv-infected children have lower frequencies of CD8+ mucosal-associated invariant T (MAIT) cells that correlate with innate, Th17 and Th22 cell subsets. PLoS One 11, e0161786 (2016).

  200. 200.

    Freeman, M. L., Morris, S. R. & Lederman, M. M. CD161 expression on mucosa-associated invariant T cells is reduced in HIV-infected subjects undergoing antiretroviral therapy who do not recover CD4+ T. cells. Pathog. Immun. 2, 335–351 (2017).

  201. 201.

    Gaardbo, J. C. et al. Increased tryptophan catabolism is associated with increased frequency of CD161+Tc17/MAIT cells and lower CD4+ T-cell count in HIV-1 infected patients on cART after 2 years of follow-up. J. Acquir. Immune Defic. Syndr. 70, 228–235 (2015).

  202. 202.

    Vinton, C. et al. Mucosa-associated invariant T cells are systemically depleted in simian immunodeficiency virus-infected rhesus macaques. J. Virol. 90, 4520–4529 (2016).

  203. 203.

    Juno, J. A. et al. MAIT cells upregulate α4β7 in response to acute simian immunodeficiency virus/simian HIV infection but are resistant to peripheral depletion in pigtail macaques. J. Immunol. 202, 2105–2120 (2019).

  204. 204.

    Paquin-Proulx, D. et al. MAIT cells are reduced in frequency and functionally impaired in human T lymphotropic virus type 1 infection: potential clinical implications. PLoS One 12, e0175345 (2017).

  205. 205.

    Renand, A. et al. Immune alterations in patients with type 1 autoimmune hepatitis persist upon standard immunosuppressive treatment. Hepatol. Commun. 2, 968–981 (2018).

  206. 206.

    Braudeau, C. et al. Persistent deficiency of circulating mucosal-associated invariant T (MAIT) cells in ANCA-associated vasculitis. J. Autoimmun. 70, 73–79 (2016).

  207. 207.

    Li, J. et al. The frequency of mucosal-associated invariant T cells is selectively increased in dermatitis herpetiformis. Australas. J. Dermatol. 58, 200–204 (2017).

  208. 208.

    Hegde, P. et al. Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver. Nat. Commun. 9, 2146 (2018).

  209. 209.

    Jiang, X. et al. The immunobiology of mucosal-associated invariant T cell (MAIT) function in primary biliary cholangitis: regulation by cholic acid-induced Interleukin-7. J. Autoimmun. 90, 64–75 (2018).

  210. 210.

    Meggyes, M. et al. The possible role of CD8+/Vα7.2+/CD161++ T (MAIT) and CD8+/Vα7.2+/CD161lo T (MAIT-like) cells in the pathogenesis of early-onset pre-eclampsia. Am. J. Reprod. Immunol. 79, (2018).

  211. 211.

    Teunissen, M. B. M. et al. The IL-17A-producing CD8+ T-cell population in psoriatic lesional skin comprises mucosa-associated invariant T cells and conventional T cells. J. Invest. Dermatol. 134, 2898–2907 (2014).

  212. 212.

    Hwang, H. Y., Kim, T. G. & Kim, T. Y. Analysis of T cell receptor α-chain variable region (Vα) usage and CDR3α of T cells infiltrated into lesions of psoriasis patients. Mol. Immunol. 43, 420–425 (2006).

  213. 213.

    Guggino, G. et al. IL-17 polarization of MAIT cells is derived from the activation of two different pathways. Eur. J. Immunol. 47, 2002–2003 (2017).

  214. 214.

    Wang, J. J., Macardle, C., Weedon, H., Beroukas, D. & Banovic, T. Mucosal-associated invariant T cells are reduced and functionally immature in the peripheral blood of primary Sjögren’s syndrome patients. Eur. J. Immunol. 46, 2444–2453 (2016).

  215. 215.

    Chiba, A. et al. Activation status of mucosal-associated invariant T cells reflects disease activity and pathology of systemic lupus erythematosus. Arthritis Res. Ther. 19, 58 (2017).

  216. 216.

    Mekinian, A. et al. Mucosal-associated invariant cells are deficient in systemic sclerosis. Scand. J. Immunol. 86, 216–220 (2017).

  217. 217.

    Sundström, P. et al. Tumor-infiltrating mucosal-associated invariant T (MAIT) cells retain expression of cytotoxic effector molecules. Oncotarget 10, 2810–2823 (2019).

Download references

Acknowledgements

This work was supported by the National Health and Medical Research Council of Australia (NHMRC; 1113293 and 1140126); the Australian Research Council (ARC; CE140100011) and the Cancer Council of Victoria (#). DIG is supported by NHMRC Senior Principal Research Fellowship (1117766). H-F.K is supported by an NHMRC ECF Fellowship (1160333).

Author information

Correspondence to Dale I. Godfrey.

Ethics declarations

Competing interests

J.M. is a named inventor on patents: US 10011602B2 (PCT No. WO2014/005194) The University of Melbourne, University of Queensland and Monash University; US 10245 262B2 (PCT No. WO201/149130) The University of Melbourne, University of Queensland and Monash University.

Additional information

Peer review information: Jamie D. K. Wilson was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark